Attovia raises $289M in upsized Nasdaq IPO
What's the deal? Attovia Therapeutics, a clinical-stage biopharmaceutical company, priced its upsized initial public offering of 17,000,000 shares at $17.00 per share, raising $289 million in gross proceeds. The stock begins trading on the Nasdaq Global Market on August 5, 2026, under the symbol "ATTO."
Why now? The San Carlos, California-based company is advancing multiple drug candidates through clinical and IND-enabling studies. An IPO gives it the capital to fund those trials, which are costly and multi-year for a company with no approved products yet.
What's the endgame? Attovia develops biotherapeutics for immune-mediated diseases, all discovered through its ATTOBODY biparatopic platform. Its lead program, ATTO-1310, is an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases.
The pipeline also includes ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 for atopic dermatitis, and ATTO-1091, a trispecific antibody for inflammatory bowel disease. Both are in IND-enabling studies.
Who's backing it? Morgan StanleyDealroom has a profile for this one. Try Dealroom →, Leerink PartnersDealroom has a profile for this one. Try Dealroom →, CitiDealroom has a profile for this one. Try Dealroom →, and RBC Capital MarketsDealroom has a profile for this one. Try Dealroom → are joint book-running managers, with LifeSci CapitalDealroom has a profile for this one. Try Dealroom → acting as passive book-running manager. Attovia has granted underwriters a 30-day option to buy up to 2,550,000 additional shares.
The signal: The upsized offering points to solid investor appetite for immune-disease biotech, a field where antibody platforms targeting inflammation remain a competitive draw. The offering is expected to close on August 6, 2026, subject to customary conditions.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
